Overview of mRNA vaccine technology and what has been implemented in SMOBIO

SMOBIO Technology Inc. 2022-02-17


    The mRNA vaccine comes from a molecular engineering ensemble where RNA substance respective to target antigens is produced by in-vitro transcribing from a DNA vector built-in with its corresponding DNA sequence. The overall structure of messenger RNA (mRNA, from 5’to 3’ end) contains cap, 5’untranslated region (5’-UTR), open reading frame (ORF) of target antigen, 3’-UTR, and poly(A) tail. Owing to cell-free manufacturing, in-vitro transcribed RNA requires further processing to turn into applicable mRNA through capping and poly-adenylation. The principal of mRNA vaccine is different from traditional vaccine. With appropriate delivery technology entering into cell cytoplasm, target antigen based on mRNA code will be made by intrinsic translation machinery and then trigger immunity.

    The advantage of mRNA vaccine relies on its fast development cycle and ease of gene synthesis, which enables to combat emerging and mutation-prone virus transmission such as SARS-CoV-2 pandemic. With the successful clinical experience in safety and efficacy of mRNA vaccines against COVID-19 by Pfizer/BioNTech and Moderna, mRNA technology has drawn world-wide attention and shown more promising in its development.    Compared to other types of vaccine, development of mRNA vaccines needs more efforts on building its delivery system, preservation, and storage condition as well. The key technical workflows of mRNA vaccine are listed in following sections.

CMS - a big picture

Illustration of mRNA vaccine production: from DNA manufacturing, mRNA production, to LNP package and then cold-chain storage

Sample 3 for three columns

3. mRNA biologics and cold chain storage

(Detailed introduction)

Technical highlight of SMOBIO in mRNA vaccine production
     We have made mRNA-encoded eGFP and encapsulated it with LNP, then conducted functional test of mRNA-LNP in vitro. From cell based assay, it clearly displayed green fluorescent signal in living cells and broad expression efficiency by flow cytometry assessment (shown in following figures).  This demonstrated that SMOBIO has ability and capability of mRNA-LNP manufacturing. Over past 2-year COVID pandemic, we hope to contribute our efforts on mRNA vaccine-related fields in Taiwan and world wide.

CMS - a big picture
CMS - a big picture

DNA plasmid manufacturing

1 DNA plasmid manufacturing

1.1  Plasmid DNA mutagenesis and construction in response to rapid virus evolution

1.2  Plasmid DNA mass production, including:

Endotoxin removal
(2)  RNA removal
(3)   Genomic DNA removal

1.3 Current available DNA constructs

(1)  Pfizer/BNT CoV-2 spike protein prefusion form, full length (Including Delta, C2, Mu derived mutants)
(2)  Moderna CoV-2 spike protein prefusion form, full length
(3)  SMOBIO in-house designed CoV-2 spike protein prefusion form, full length(With longer poly(A) tails )
(4)   EGFP reporter construct

1.4 Schematic view of available DNA template system (built with original DNA coding sequence)

CMS - a big picture

Sequence Map Download:

pSK-BNT-Swt (based on BNT designed spike coding sequence and backbone)  (Download)

pSK-Moderna-Swt (based on Moderna designed spike coding sequence) (Download)

pSK-SMBiO-Swt (SMOBIO in-house cassette design) (Download)

pSK-GFP (containing EGFP coding sequence(Download)

2.  mRNA synthesis

2.1 In vitro transcription:

(1) T7 RNA polymerase

Text and image block

(2) RNase inhibitor

Text and image block

(3) mRNA nucleotide building blocks:

NTP: ATP, UTP, CTP, GTP, ψTP, N1-methyl ψTP Nucleoside: ribose of A, U, C, G, ψ, N1-methyl ψ.

CMS - a big picture

HPLC real-time monitoring for ψTP production

CMS - a big picture

HPLC real-time monitoring for N1mψ0P production

CMS - a big picture

HPLC real-time monitoring for N1mψ0P production

Mass, NMR data are listed below: 

CMS - a big picture
ψ (pseudouridine) Mass spectrometry
CMS - a big picture
ψ (pseudouridine) Hydrogen NMR
CMS - a big picture
Pseudouridine carbon-13 NMR (13C NMR)

(4) Vaccinia caping enzyme: including D1, D12 subunit

Text and image block


Text and image block

(6)Inorganic Pyrophosphatase
Text and image block

2.2 mRNA extraction: oligo-dT resin: developing in progress

3.  mRNA-LNP manufacturing

(1) key data about cationic lipid production
    ALC 0315 cationic lipid production

CMS - a big picture
ALC-0315 Mass spectrometry
CMS - a big picture
ALC-0315 hydrogen NMR

CMS - a big picture
ALC-0315 Carbon 13-NMR

In-house synthesized ALC0315 lipid were presented as (A) original form and (B) dissolved in ethanol.

CMS - a big picture

(2)mRNA-LNP preparation by using microfluidic system

CMS - a big picture